Endpoints News

Leadership changes at Bicara		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

14 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by

The debate of durability in nAMD

news

FDA approves Bristol Myers' multiple myeloma successor

Peer Review

Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board

Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo

Aug 19

1:00 pm ET

From pilots to production: AI across R&D, safety, regulatory, and clinical

in case you missed it

'Incorrect and misleading' data prompted regulators' decision to pull Tavneos from Europe

PDUFA VIII commitments: 'America First' provisions, faster reviews and more

Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest

PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction

Karyopharm has a month left to salvage its cancer expansion plans

News Briefing

Zealand's royalty deal; Khartis raises money for TED drug

Novo CEO says obesity market won't be winner-take-all battle with Lilly

Recently discovered genetic variants seem to protect against Alzheimer’s disease, suggesting a path toward a cure. But are their powers believable?

Science

Endpoints cancer experts Nicole DeFeudis and Ayisha Sharma will be in Madrid in October for this year's ESMO meeting. If you have any news to share please get in touch with them!